Compare MDAI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDAI | KYNB |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | 78 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 31.9M |
| IPO Year | N/A | N/A |
| Metric | MDAI | KYNB |
|---|---|---|
| Price | $1.44 | $7.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 731.6K | 29.0K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $63.80 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $6.32 |
| 52 Week High | $3.21 | $9.58 |
| Indicator | MDAI | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 54.04 |
| Support Level | $1.25 | $6.68 |
| Resistance Level | $1.48 | $7.58 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 42.58 | 86.55 |
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.